Taking Care of Family, Clients & Community for Three Decades
Let's Connect

Retina Health Center first to offer Yutiq, new treatment for uveitis, a form of eye inflammation

Retina Health Center is one of the first to offer Yutiq, a micro-insert drug delivery recently approved by the U.S. Food and Drug Administration for the treatment of uveitis, a form of eye inflammation that affects the middle layer of tissue in the eye wall (uvea). The third leading cause of blindness, uveitis may be caused by infection, injury, or an autoimmune or inflammatory disease. The current standard of care is local corticosteroids, and recurrent flare-ups are common.

“We are honored to be one of the first center in the U.S. to offer Yutiq to patients,” said Dr. Alexander Eaton, founder and director of Retina Health Center. “This new drug delivery is a positive advancement for those suffering with uveitis which causes swelling and destroys the eye tissue and can ultimately lead to blindness. I’m very encouraged by the results of Yutiq in delivering consistent dosing and lowering recurrence rates for patients. Our patients are excited about the reduction in treatment burden that can be achieved and can’t wait to get started.”

Retina Health Center and the Macular Degeneration Research Center were established in 2002 by Dr. Alexander M. Eaton, a long-time Southwest Florida resident, who has been practicing ophthalmology in Lee and Collier counties for more than 20 years. Dr. Eaton has been the principal investigator for numerous studies to prevent and treat macular degeneration, and has invented numerous medical devices for use by patients and physicians that are used worldwide. For more information on the latest studies or to make an appointment, call 239-337-3337 in Fort Myers or 239-793-5200 in Naples, or visit www.retinahealthcenter.com.

Share now!

More To Explore

Client News

Fischer Family Foundation opens 2025 grant cycle

The Fischer Family Foundation, a foundation that supports underprivileged and low-income populations ages 8-25, is now accepting submissions for its 2025 grant cycle. The grant